MTOR and ovarian carcinoma: Mutations in the p110 subunit of PI3K, called PIK3CA, are often responsible for activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and have been detected in 12% of ovarian cancers [56].